Kelsey Goodwin
Stock Analyst at Guggenheim
(2.75)
# 1,927
Out of 4,931 analysts
15
Total ratings
66.67%
Success rate
15.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kelsey Goodwin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| URGN UroGen Pharma | Maintains: Buy | $15 → $30 | $18.59 | +61.38% | 3 | Jun 13, 2025 | |
| IPSC Century Therapeutics | Reiterates: Buy | n/a | $0.53 | - | 3 | Mar 28, 2025 | |
| GNLX Genelux | Initiates: Buy | $8 | $3.34 | +139.52% | 1 | Oct 29, 2024 | |
| NUVL Nuvalent | Maintains: Buy | $99 → $105 | $72.16 | +45.51% | 2 | Sep 16, 2024 | |
| MGNX MacroGenics | Downgrades: Neutral | n/a | $1.61 | - | 1 | Jul 31, 2024 | |
| ACLX Arcellx | Maintains: Buy | n/a | $71.15 | - | 3 | Jun 20, 2023 | |
| LEGN Legend Biotech | Initiates: Neutral | n/a | $37.43 | - | 1 | Oct 31, 2022 | |
| IOVA Iovance Biotherapeutics | Initiates: Neutral | n/a | $2.64 | - | 1 | Oct 31, 2022 |
UroGen Pharma
Jun 13, 2025
Maintains: Buy
Price Target: $15 → $30
Current: $18.59
Upside: +61.38%
Century Therapeutics
Mar 28, 2025
Reiterates: Buy
Price Target: n/a
Current: $0.53
Upside: -
Genelux
Oct 29, 2024
Initiates: Buy
Price Target: $8
Current: $3.34
Upside: +139.52%
Nuvalent
Sep 16, 2024
Maintains: Buy
Price Target: $99 → $105
Current: $72.16
Upside: +45.51%
MacroGenics
Jul 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.61
Upside: -
Arcellx
Jun 20, 2023
Maintains: Buy
Price Target: n/a
Current: $71.15
Upside: -
Legend Biotech
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $37.43
Upside: -
Iovance Biotherapeutics
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $2.64
Upside: -